Navigation Links
Kimmel Cancer Center at Jefferson breast cancer symposium features latest in research, treatment
Date:4/6/2011

PHILADELPHIAThe latest advances in both breast cancer treatment and research including innovations in diagnostic, surgical, chemotherapy and radiation approaches will be discussed Friday, April 8, 2011, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.

The all-day, breast cancer symposium, part of an annual series at the Kimmel Cancer Center, will be held at the Bluemle Life Sciences Building, 233 S. 10th Street, beginning at 8:30 a.m.

"Treating breast cancer is a multidisciplinary effort, with input from a variety of specialists, such as pathologists, surgeons, radiation oncologists, and medical oncologists, who make decisions about patient treatment and care," says Richard Pestell, M.D., Ph.D., director of the Kimmel Cancer Center at Jefferson and professor and chair of cancer biology at Jefferson Medical College of Thomas Jefferson University.

"This symposium is an opportunity for those players to come together and highlight the innovative discoveries we believe will be important for the next generation of therapeutics in breast cancer patients," he adds.

A range of topics will be covered by top experts here at Jefferson and other institutions in the United States.

Michael Lisanti, M.D., professor of cancer biology at Jefferson Medical College, will discuss his recent work with new models for cancer, "The Reverse Warburg Effect" and "The Autophagic Tumor Stroma Model of Cancer." His studies have shown how mitochondrial oxidative stress plays a role in cancer development and how cancer metabolism can be used to predict clinical outcomes.

"High-risk breast cancer patientsthose whose cancer cells use high-energy metabolitescan be treated with new therapeutics that target oxidative mitochondrial metabolism," Dr. Lisanti said. "We should re-consider using antioxidants and autophagy inhibitors as anti-cancer agents."

There will also be presentations by Hallgeir Rui, M.D., Ph.D, also of the department of cancer biology at Jefferson Medical College, who will discuss therapy-relevant stratification of breast cancer, and Paula Ryan, M.D., Ph.D., of Fox Chase Cancer Center's department of medical oncology, who will present a clinical update on patients with triple negative breast cancer, a high-risk disease that is characterized as more aggressive and less responsive to standard treatment.

Hyman B. Muss, M.D., of the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill School of Medicine, will lead a session titled "Geriatrics: Treating the Elderly with Breast Cancer."

Sixty percent of cancer in the United States occurs in persons aged 65 and older. At the same time, senior patients may have acute or chronic diseases that make treating their cancer challenging. That's why the Kimmel Cancer Center at Jefferson established the new, multidisciplinary Senior Adult Oncology Center to provide a comprehensive consultation for senior patients in order to meet those special challenges.


'/>"/>

Contact: Steve Graff
stephen.graff@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Breast inflammation is key to cancer growth, Kimmel Cancer Center researchers say
2. New fusion gene plays role in some stomach cancers
3. New prostate cancer test gives more accurate diagnosis
4. Robotic surgery put to the test for bowel cancer
5. Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network
6. New drug shrinks cancer in animals, U-M study shows
7. Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen
8. Fox Chase researchers report that naproxen reduces tumors in a mouse model of colon cancer
9. Overall Health May Be Key to Beating Breast Cancer
10. Immune-Boost Treatment Might Help Some With Advanced Colon Cancer
11. An international study in China finds strawberries may slow precancerous growth in the esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
(Date:2/5/2016)... ... ... Colorize is a web theme package created exclusively for Final ... dynamic moving camera. Colorize is perfect for personal and web related videos and its ... to 5 focus points per scene, stage floor scene presets that are great for ...
(Date:2/5/2016)... ... 2016 , ... Health and wellness is a topic that should concern all ... are experiencing an illness. Migraines are a severe form of a headache and often ... not wish the pain on their worst enemy, the feeling can last for many ...
(Date:2/5/2016)... Ramsey, NJ (PRWEB) , ... February 05, 2016 ... ... Optimizing Primary Care for Patients with Rare Diseases, a continuing medical education (CME) ... conference is the first of its kind—and a first for ACCORD, whose mission ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ... Development event in New York City on Thursday, January 21, 2016. Kingsley ... Mediacom, (both alumnus of the varsity Columbia soccer program) spoke at the event, ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016 Dehaier Medical Systems ... the "Company"), which develops, markets and sells medical ... China and international markets, today ... aims to concentrate the Company,s resources to develop ... business and to focus more on its major ...
(Date:2/5/2016)... Site Profile: --> Site ... People, announced their latest primary healthcare case study where speech recognition ... and to save the practice money. Site Profile: ... Challenge: --> ,- Wirral CCG ,- VoicePower client since ... Wirral CCG ,- VoicePower client since 2013 Challenge: ...
(Date:2/4/2016)... 2016  Edwards Lifesciences Corporation (NYSE: EW ), ... disease and critical care monitoring, announced today that it ... with Morgan Stanley & Co. LLC to repurchase $325 ... of the Company,s previously authorized program to repurchase up ... --> --> Under ...
Breaking Medicine Technology: